Next Article in Journal
Are We Finally Moving toward Personalized Therapy in Colorectal Cancer?
Previous Article in Journal
Optimizing Biologic Sequencing in Metastatic Colorectal Cancer: First Line and Beyond
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue s1
10.3747/co.26.5605
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Adjuvant Therapy for Stages II and III Colon Cancer: Risk Stratification, Treatment Duration, and Future Directions

by
U. Bender
1,
Y.S. Rho
2,
I. Barrera
1,
S. Aghajanyan
1,
J. Acoba
2,3 and
P. Kavan
1,4,*
1
Gerald Bronfman Department of Oncology, McGill University Faculty of Medicine, Montreal, QC, Canada
2
University of Hawaii Internal Medicine Program, Honolulu, HI 96822, USA
3
University of Hawaii Cancer Center, Honolulu, HI 96822, USA
4
E-783.2 Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, QC H3T 1E2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(s1), 43-52; https://doi.org/10.3747/co.26.5605
Submission received: 13 August 2019 / Revised: 4 September 2019 / Accepted: 9 October 2019 / Published: 1 November 2019

Abstract

Background: To date, the role of adjuvant systemic therapy in stages ii and iii colon cancer remains a topic of interest and debate. The objective of the present review was to assess the most recent data, specifically addressing methods of risk stratification, duration of therapy, and future directions. Methods: PubMed and medline were searched for literature pertinent to adjuvant chemotherapy in either stage ii or stage iii colorectal cancer. Summary: Locoregional disease, histopathology, age, laterality, and a number of other biologic and molecular markers appear to have a role in disease risk stratification. The duration of adjuvant therapy for stage iii disease can vary based on risk factors, but use of adjuvant therapy and duration of therapy in stage ii disease remain controversial. Future directions should include genomic assays and improved study design to provide concrete evidence about the duration of adjuvant folfox or capox and about other types of chemotherapy and immunotherapy.
Keywords: adjuvant chemotherapy; treatment duration; risk stratification; colorectal cancer adjuvant chemotherapy; treatment duration; risk stratification; colorectal cancer

Share and Cite

MDPI and ACS Style

Bender, U.; Rho, Y.S.; Barrera, I.; Aghajanyan, S.; Acoba, J.; Kavan, P. Adjuvant Therapy for Stages II and III Colon Cancer: Risk Stratification, Treatment Duration, and Future Directions. Curr. Oncol. 2019, 26, 43-52. https://doi.org/10.3747/co.26.5605

AMA Style

Bender U, Rho YS, Barrera I, Aghajanyan S, Acoba J, Kavan P. Adjuvant Therapy for Stages II and III Colon Cancer: Risk Stratification, Treatment Duration, and Future Directions. Current Oncology. 2019; 26(s1):43-52. https://doi.org/10.3747/co.26.5605

Chicago/Turabian Style

Bender, U., Y.S. Rho, I. Barrera, S. Aghajanyan, J. Acoba, and P. Kavan. 2019. "Adjuvant Therapy for Stages II and III Colon Cancer: Risk Stratification, Treatment Duration, and Future Directions" Current Oncology 26, no. s1: 43-52. https://doi.org/10.3747/co.26.5605

APA Style

Bender, U., Rho, Y. S., Barrera, I., Aghajanyan, S., Acoba, J., & Kavan, P. (2019). Adjuvant Therapy for Stages II and III Colon Cancer: Risk Stratification, Treatment Duration, and Future Directions. Current Oncology, 26(s1), 43-52. https://doi.org/10.3747/co.26.5605

Article Metrics

Back to TopTop